Asian responders rescue motesanib in NSCLC but Amgen offloads rights to Takeda
This article was originally published in Scrip
The failure of Amgen/Takeda's motesanib in the Phase III MONET1 study in advanced non-squamous non-small cell lung cancer (NSCLC) last year could have dealt the final blow to the molecule in this indication, for which most analysts were already assuming zero sales.
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context